Condition: Atrial Fibrillation · Sponsor: Atrial Fibrillation Network
EASThigh-AFNET 11 is an international, prospective, randomized, open, blinded endpoint assessment, multicenter trial (Treatment Strategy trial). The objective of EASThigh-AFNET 11 is to investigate whether early atrial fibrillation ablation in patients with atrial fibrillation (AF) and a high comorbidity burden (CHA2DS2-VASc ≥4) reduces cardiovascular events (stroke, cardiovascular death, or heart failure events) compared to usual care.
This description comes directly from the study's public registry record.
Antje Albring, Dr. · +49 251 980 1330 · easthigh@af-net.eu
Anna-Katharina Quade · +49 251 980 1330 · easthigh@af-net.eu
Always discuss trial participation with your own doctor first.
| Several sites | Multiple Locations, Australia | Not Yet Recruiting |
| Several sites | Multiple Locations, Canada | Recruiting |
| Several sites | Multiple Locations, Germany | Recruiting |
| Several sites | Multiple Locations, Netherlands | Recruiting |
| Several sites | Multiple Locations, Poland | Recruiting |
| Several sites | Multiple Locations, Spain | Recruiting |
| Several sites | Multiple Locations, United Kingdom | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06324188